Braveheart Bio (BRVE) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Nov 2026. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Act EPS | Act rev | Reaction |
|---|---|---|---|
| Nov 10, 2026press release, after close · 4:03 pm ET | −0.51 | $0.00 | +6.5%next session |
| Sep 8, 2026press release, after close · 4:03 pm ET | −2.51 | $0.00 | −1.7%next session |
| Nov 4, 2025 E | −10.05 | $0.00 | —estimated date |
| Aug 4, 2025 E | −0.14 | $0.00 | —estimated date |
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 2 | 1 | 4 | 4 |
| Avg estimate | −0.45 | −0.36 | −1.97 | −1.51 |
| Low estimate | −0.45 | −0.36 | −2.75 | −1.66 |
| High estimate | −0.45 | −0.36 | −0.70 | −1.35 |
| Year-ago EPS | — | — | — | −1.97E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 0 | 0 | 0 |
| Avg estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Low estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| High estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Year-ago revenue | — | — | — | $0.00E |
| Implied growth | — | — | — | — |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.45 | −0.36 | −1.97 | −1.51 |
| 7 days ago | — | — | — | — |
| 30 days ago | — | — | — | — |
| 60 days ago | — | — | — | — |
| 90 days ago | — | — | — | — |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus has held at $−0.45 across 1 tracked day since Nov 15, 2026. A bar that has not moved is an answer, not a gap: a beat against a flat bar is a real beat. Per-analyst up/down revision counts aren't in our data feed.
Common questions
What were Braveheart Bio's latest quarterly earnings?
Braveheart Bio reported diluted EPS of −0.51 and revenue of $0.00 on Nov 10, 2026.
How did Braveheart Bio's stock move after its last earnings report?
Braveheart Bio moved +6.5% in the session after its Nov 10, 2026 report.

